Dr Robert Barnes, Chartered FCSI(Hon)

2023 Apr  CISI awards Honorary Fellowship, its highest accolade, to Dr Robert Barnes, https://www.cisi.org/cisiweb2/cisi-website/about-us/press-release/2023/04/19/cisi-awards-five-new-honorary-fellowships

2023 Feb  UKJT Legal Statement on Digital Securities: Experts’ Voices – Dr Robert Barnes at 1:47 & 4:37, https://www.youtube.com/watch?v=Ul1FK0TB2xk

2022 Nov  Dr Robert Barnes is voted The TRADE’s first Industry Person of the Year, https://www.thetradenews.com/dr-robert-barnes-is-voted-the-trades-first-industry-person-of-the-year/ and https://www.thetradenews.com/industry-legend-robert-barnes-to-leave-lsegs-turquoise/

2022 Jul  Dr Robert Barnes receives European Markets Choice Award for Individual Market Recognition, https://www.bestexecution.net/dr-robert-barnes-set-to-leave-lseg-at-the-end-of-the-year/

Dr Robert Barnes is Founder and Managing Director of Anopolis, a specialised advisory boutique since 2013, and an exchange expert with more than 29 years in financial markets including 13 years as CEO of two successful regulated trading venues – Turquoise (2013-2022, LSEG) & UBS MTF (2010-2013, UBS 1994-2013). He serves as a current member of the UK FCA Secondary Markets Advisory Committee and the National Timing Centre programme Steering Committee led by the National Physical Laboratory.

Best Execution Magazine describes Dr Barnes as “a leading light and well-respected figure on the financial service landscape. He is known as a lifelong champion of listening to customers and for innovation in partnership to achieve greater market efficiencies on a global scale.”

As CEO, Dr Barnes transformed Turquoise – majority owned by LSEG – into a profitable innovative client-focused organization, achieving record results, and winning the Financial News Excellence in Trading & Technology Award for Most Innovative Product/Service in 2015 and Financial Technology Innovation of the Year in 2022; and The TRADE Leaders in Trading Awards for Block Trading Venue in 2017 and Outstanding Equities Trading Venue in 2021. Prior to joining LSEG in 2013, Dr Barnes worked at UBS from 1994 and has extensive and varied experience of leading business and providing strategic direction, having become a Managing Director, Equities, by 2005 and in 2010 became founding CEO of UBS MTF which grew to #1 among peers, https://www.fnlondon.com/articles/ubs-mtf-proves-clearing-choice-delivers-an-edge-20120723

He is an expert in market structures, having held a wide range of key advisory and policy roles in financial services, including as Chairman of the Securities Trading Committee of the London Investment Banking Association 2004-2009; FSA’s Capital Markets Senior Practitioner Committee from 2005-2008; European Commission’s Clearing and Settlement Advisory and Monitoring Expert Groups (“CESAME”) 1 & 2 from 2007-2010; FTSE Country Classification Committee from 2007-2016; Chairman of TheCityUK Turkey Advisory Group 2012-2020; Co-Chairman of the EMEA Regional Committee of FIX Trading Community 2014-2016; TheCityUK Switzerland Advisory Group 2019-2022; Practitioner Member of the Financial Markets Law Review Panel for Capital Markets Authority of Kenya from 2019; and Non Executive Director of British Pearl from 2020 – rebranding as BPX, a digital platform for real estate in 2023 as one of the first alternate asset business models embracing the clarity provided by the UK Jurisdiction Taskforce’s Legal Statement on Digital Securities published in 2023. Dr Barnes of Anopolis and as Chartered Fellow of the Chartered Institute for Securities & Investment, featured as one of the Experts’ Voices in the video by LawtechUK and Oxera on Digital Securities and English Law: https://www.youtube.com/watch?v=Ul1FK0TB2xk. During his career, Dr Barnes has had the privilege to address by invitation audiences of authorities and practitioners, students and members of the public in 40 countries.

Robert is a Chartered Honorary Fellow of the Chartered Institute for Securities & Investment and holds a PhD in Biotechnology from Cambridge University and a BA in Biochemical Sciences from Harvard.

Dr Barnes remains involved in biotechnology and biochemical sciences by serving since 2021 as a Non Executive Director of Arjuna Therapeutics, a pharmaceutical firm innovating Therapeutic Molecular Clusters as a novel class of medicines to bring new solutions to the largest unmet clinical needs of oncology.